Company news

Cellectar Biosciences, Inc. news in 2024

Cellectar Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

December 9, 2024

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

November 20, 2024

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

November 17, 2024

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

November 13, 2024

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

November 11, 2024

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

November 10, 2024

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

November 6, 2024

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

October 31, 2024

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia

August 25, 2024

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

August 22, 2024

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

August 12, 2024

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

August 7, 2024

Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

July 22, 2024

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

July 21, 2024

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape

June 26, 2024

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

May 28, 2024

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

May 13, 2024

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

May 7, 2024

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

May 6, 2024

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

March 26, 2024

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

March 19, 2024

Cellectar Biosciences to Present at the 36th Annual Roth Conference

March 13, 2024

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

March 3, 2024

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

January 29, 2024

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

January 24, 2024

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

January 21, 2024

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

January 15, 2024

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results

January 11, 2024

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

January 10, 2024

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

January 7, 2024

Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024

January 2, 2024

Calls in 2024

Decks in 2024